rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011;7(2):143-153.Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert ...
Pharming是一家商业阶段的生物制药公司,专注于于开发蛋白质替代疗法和罕见病的精准治疗。 公司的核心管线RUCONEST®是重组人C1酯酶抑制剂(recombinant human C1 esterase inhibitor,rhC1INH),是第一个也是唯一的无血浆rhC1INH蛋白替代疗法,C1INH是一种天然存在的蛋白质,它可以下调补体的级联反应,从而控制受影响部位的...
rcc-rhC1INH 和ox-rhC1INH 2 种对照品质量浓度为0.2、1 和 1.4 mg ·mL-1 时的回收 率均在85%~115% 的范围内。对同1 批3 个待测样品进行测定,rcc-rhC1INH 含量为(0.082 ±0.008 )% , RSD 为9.8% ;ox-rhC1INH 含量为(0.35 ±0.05 )% ,RSD 为14.3%,显示该方法具有较好的专属性、准确性 和...
事后分析显示,在接受大量造影剂的PCI亚组患者中,与安慰剂组相比,rhC1INH组的尿NGAL中位绝对峰值和相对峰值明显小于安慰剂组(1.8 ng/ml[IQR:-2.7-12.5] vs.26.2 ng/ml[IQR:16.0-133.8];P=0.039;11%[IQR:-5%-74%] vs.205%[IQR:84%-469%];P=0.002),而在非PCI患者中无明显差异。 次要终点方面,RhC1...
rhC1INH Cuts Attack Frequency in Hereditary AngioedemaNewsJaapa
Results The NMA fixed effects model found no significant differences in time to beginning of symptom relief between sebetralstat 300 mg and IV-rhC1-INH 50 IU/kg (HR [95% CI] 0.96 [0.42-2.15] to 1.19 [0.58-2.45]). After adjusting for baseline attack severity, MAIC showed numerically ...
Clinical studies of recombinant human Cl inhibitor (rhC1-INH) in patients with acute attacks of hereditary angioedema [abstract]. J Allergy Clin Immunol 2008; 121(3): 797Nuijens J, Verdotik R, Gianneti C, et al. Clinical studies of recombinant human C1 inhibitor (rhC1INH) in ...
rhC1inh was well tolerated (no allergic reactions) and showed the desired biological activity (C4 increases and inhibition of C4b/c formation) and will be tested in phase II studies in patients with severe attacks of angioedema. Clinical Pharmacology & Therapeutics (2004) 75 , P52鈥揚52; doi...
rhC1inh was well tolerated (no allergic reactions) and showed the desired biological activity (C4 increases and inhibition of C4b/c formation) and will be tested in phase II studies in patients with severe attacks of angioedema. Clinical Pharmacology & Therapeutics (2004) 75 , P52鈥揚52; doi...
Recombinant Human C1 Inhibitor (rHC1INH) Is Efficacious and Well Tolerated As Prophylaxis for Prevention of Hereditary Angioedema (HAE) Attacks: A Randomized, Phase 2 TrialAim: To determine the frequency of diabetic ketoacidosis in diabetic patients presenting in a tertiary care setting and frequency...